Prognostic models for chronic lymphocytic leukaemia: an exemplar systematic review and meta‐analysis

This is the protocol for a review and there is no abstract. The objectives are as follows: Primary objective The objective of this systematic review is to identify, describe and appraise all prognostic models developed to predict overall or progression-free survival in patients with CLL. If enough models for the same type of outcome are present, we will meta-analyse performance of the models.

[1]  G. Collins,et al.  Effect of Ebola Progression in Liberia , 2015, Annals of Internal Medicine.

[2]  G. Collins,et al.  Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modelling Studies: The CHARMS Checklist , 2014, PLoS medicine.

[3]  H. Döhner,et al.  Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. , 2014, Blood.

[4]  Andrew W. Greaves,et al.  Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia. , 2014, Blood.

[5]  Douglas G. Altman,et al.  Improving the Transparency of Prognosis Research: The Role of Reporting, Data Sharing, Registration, and Protocols , 2014, PLoS medicine.

[6]  Karel G M Moons,et al.  Meta‐analysis and aggregation of multiple published prediction models , 2014, Statistics in medicine.

[7]  R. Fanin,et al.  Bendamustine in chronic lymphocytic leukemia: Outcome according to different clinical and biological prognostic factors in the everyday clinical practice , 2013, American journal of hematology.

[8]  M. Cazzola,et al.  Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. , 2012, Blood.

[9]  Karel G M Moons,et al.  Aggregating published prediction models with individual participant data: a comparison of different approaches , 2012, Statistics in medicine.

[10]  J. Byrd,et al.  Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Steyerberg,et al.  Reporting and Methods in Clinical Prediction Research: A Systematic Review , 2012, PLoS medicine.

[12]  M. Leeflang,et al.  Search Filters for Finding Prognostic and Diagnostic Prediction Studies in Medline to Enhance Systematic Reviews , 2012, PloS one.

[13]  K. Do,et al.  Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  H. Döhner,et al.  Importance of genetics in chronic lymphocytic leukemia. , 2011, Blood reviews.

[15]  M. Hallek,et al.  Optimal Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia , 2011, Drugs & aging.

[16]  T. Haferlach,et al.  Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters , 2010, Genes, chromosomes & cancer.

[17]  E. Montserrat,et al.  Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[19]  D. Catovsky,et al.  Disease burden of chronic lymphocytic leukaemia within the European Union , 2008, European journal of haematology.

[20]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[21]  A. Pettitt,et al.  The role of prognostic factors in assessing ‘high-risk’ subgroups of patients with chronic lymphocytic leukemia , 2007, Leukemia.

[22]  P. Solal-Céligny.  Follicular Lymphoma International Prognostic Index. , 2004, Current treatment options in oncology.

[23]  T. Shanafelt,et al.  clinical practice for patients with CLL Prognosis at diagnosis : integrating molecular biologic insights into , 2003 .

[24]  Emili Montserrat,et al.  ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. , 2003, The New England journal of medicine.

[25]  A Benner,et al.  Genomic aberrations and survival in chronic lymphocytic leukemia. , 2000, The New England journal of medicine.

[26]  E. Newcomb,et al.  p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression , 1993 .

[27]  N. Chiorazzi,et al.  mechanisms of disease Chronic Lymphocytic Leukemia , 2010 .

[28]  Mark J. Thomas,et al.  A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis , 1981, Cancer.

[29]  E. Cronkite,et al.  Clinical staging of chronic lymphocytic leukemia. , 1975, Blood.